Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

At a glance: The ONWARDS insulin icodec trials

A round-up of the ONWARDS phase 3 clinical trials evaluating the novel weekly insulin icodec in people with diabetes.
ADVANCED SEARCH
Log in
Top
Clinical and Translational Oncology
Published in: Clinical and Translational Oncology 12/2020

01-12-2020 | Metastasis | Brief Research Article

Stereotactic body radiation therapy for liver metastasis from colorectal cancer: size matters

Authors: S. Flamarique, M. Campo, G. Asín, S. Pellejero, A. Viúdez, F. Arias

Published in: Clinical and Translational Oncology | Issue 12/2020

Login to get access

Abstract

Purpose

We analysed our initial experience with SBRT in liver metastasis from colorectal cancer at our institution.

Materials and methods

Between January/2014 and December/2017, 22 patients with 31 LMCCR were treated. Local control (LC) was assessed using the Kaplan–Meier and log-rank tests. We analysed potential prognostic factors for LC: sex, PTV size, number of LM and the radiation scheme.

Results

Median age: 69 years. Prior chemotherapy or local liver treatments: 81.8% and 63.6% of patients, respectively. SBRT consisted of 3 × 20 Gy (42.9%) and 3 × 15 Gy (31.4%). There were 88.5% responses (57.1% CR and 31.4% PR). Median follow-up was 30 months. LC per lesion at 12 and 24 months was 85.3% and 61.8%, respectively. Tumour volumes > 30 cc correlated with worsened 2-year-control rates (90% vs 34.5%) (p = 0.005). There was only a patient with CTC-grade 3 toxicity.

Conclusions

Liver SBRT is a safe and effective treatment that achieves high local control rates. We found a significant correlation between larger LMCRC and worse local control.
Literature
1.
Weiss L, Grundmann E, Torhorst J, Hartveit F, Moberg I, Eder M, et al. Haematogenous metastatic patterns in colonic carcinoma: an analysis of 1541 necropsies. J Pathol. 1986;150(3):195–203.PubMed
2.
Bellier J, De Wolf J, Hebbar M, El Amrani M, Desauw C, Leteurtre E, Truant S. Repeated resections of hepatic and pulmonary metastases from colorectal cancer provide long-term survival. World J Surg. 2018;42:1171–9.PubMed
3.
Quan D, Gallinger S, Nhan C, Auer RA, Biagi JJ, Fletcher GG, et al. The role of liver resection for colorectal cancer metastases in an era of multimodality treatment: a systematic review. Surgery. 2012;151:860–70.PubMed
4.
Chow FC, Chok KS. Colorectal liver metastases: An update on multidisciplinary approach. World J Hepatol. 2019;11:150–72.PubMedPubMedCentral
5.
Gillams AR, Lees WR. Five-year survival in 309 patients with colorectal liver metastases treated with radiofrequency ablation. Eur Radiol. 2009;19:1206–13.PubMed
6.
Cirocchi R, Trastulli S, Boselli C, Montedori A, Cavaliere D, Parisi A, et al. Radiofrequency ablation in the treatment of liver metastases from colorectal cancer. Cochrane Database Syst Rev. 2012;6:CD006317.
7.
Dawood O, Mahadevan A, Goodman KA. Stereotactic body radiation therapy for liver metastases. Eur J Cancer. 2009;45(17):2947–59.PubMed
8.
Rusthoven KE, Kavanagh BD, Cardenes H, Stieber VW, Burri SH, Feigenberg SJ, et al. Multi-institutional phase I/II trial of stereotactic body radiation therapy for liver metastases. J Clin Oncol. 2009;27:1572–8.PubMed
9.
Habermehl D, Herfarth KK, Bermejo JL, Hof H, Rieken S, Kuhn S, et al. Single-dose radiosurgical treatment for hepatic metastases—therapeutic outcome of 138 treated lesions from a single institution. Radiat Oncol. 2013;8:175.PubMedPubMedCentral
10.
Berber B, Ibarra R, Snyder L, Yao M, Fabien J, Milano MT, et al. Multicentre results of stereotactic body radiotherapy for secondary liver tumours. HPB. 2013;15:851–7.PubMedPubMedCentral
11.
Timmerman RD. An overview of hypofractionation and introduction to this issue of seminars in radiation oncology. Radiat Oncol. 2008;18(4):215–22.
12.
13.
Schwartz LH, Litière S, de Vries E, Bogaerts J, Chen A, Dancey J, et al. RECIST 1.1-Update and clarification: from the RECIST committee. Eur J Cancer. 2016;62:132–7.CrossRef
14.
15.
Schlick CJR, Merkow RP, Bentrem DJ. Nonresectional regional therapies for metastatic colorectal cancer to the liver. J Surg Oncol. 2019;119:636–41.PubMed
16.
Chang DT, Swaminath A, Kozak M, Weintraub J, Koong AC, Kim J, et al. Stereotactic body radiotherapy for colorectal liver metastases: a pooled analysis. Cancer. 2011;117:4060–9.PubMed
17.
Scorsetti M, Comito T, Tozzi A, Navarria P, Fogliata A, Clerici E, et al. Final results of a phase II trial for stereotactic body radiation therapy for patients with inoperable liver metastases from colorectal cancer. J Cancer Res Clin Oncol. 2015;141:543–53.PubMed
18.
Van Der Pool AE, Mendez Romero A, Wunderink W, Heijmen BJ, Levendag PC, Verhoef C, et al. Stereotactic body radiation therapy for colorectal liver metastases. Br J Surg. 2010;97:377–82.PubMed
19.
Hoyer M, Roed H, Traberg Hansen A, Ohlhuis L, Petersen J, Nellemann H, et al. Phase II study on stereotactic body radiotherapy of colorectal metastases. Acta Oncol. 2006;45:823–30.PubMed
20.
Joo JH, Park J, Kim JC, Yu CS, Lim SB, Park IJ, et al. Radiación therapy for liver metastases from colorectal cancer. Int J Radiat Oncol Biol Phys. 2017;99(4):876–83.PubMed
21.
Bujold A, Massey CA, Kim JJ, Brierley J, Cho C, Wong RK, et al. Sequential phase I and II trials of stereotactic body radiotherapy for locally advanced hepatocellular carcinoma. J Clin Oncol. 2013;31:1631–9.PubMed
22.
Feng M, Suresh K, Schipper MJ, Bazzi L, Ben-Josef E, Matuszak MM, et al. Individualized adaptive stereotactic body radiotherapy for liver tumors in patients at high risk for liver damage: a phase 2 clinical trial. JAMA Oncol. 2018;4:40–7.PubMed
23.
Moon DH, Wang AZ, Tepper JE. A prospective study of the safety and efficacy of liver stereotactic body radiotherapy in patients with and without prior liver-directed therapy. Radiother Oncol. 2018;126:527–33.PubMed
24.
Takeda A, Sanuki N, Tsurugai Y, Iwabuchi S, Matsunaga K, Ebinuma H, et al. Phase 2 study of stereotactic body radiotherapy and optional transarterial chemoembolization for solitary hepatocellular carcinoma not amenable to resection and radiofrequency ablation. Cancer. 2016;122:2041–9.PubMed
25.
Lasley FD, Mannina EM, Johnson CS, Perkins SM, Althouse S, Maluccio M, et al. Treatment variables related to liver toxicity in patients with hepatocellular carcinoma, Child-Pugh class A and B enrolled in a phase 1–2 trial of stereotactic body radiation therapy. Pract Radiat Oncol. 2015;5:e443–e44949.PubMed
26.
Méndez Romero A, Wunderink W, Hussain SM, De Pooter JA, Heijmen BJ, Nowak PC, et al. Stereotactic body radiation therapy for primary and metastatic liver tumors: a single institution phase I–II study. Acta Oncol. 2006;45:831–7.PubMed
27.
Stintzing S, Grothe A, Hendrich S, Hoffmann RT, Heinemann V, Rentsch M, et al. Percutaneous radiofrequency ablation (RFA) or robotic radiosurgery (RRS) for salvage treatment of colorectal liver metastases. Acta Oncol. 2013;52(5):971–7.PubMed
28.
Jackson WC, Tao Y, Mendiratta-Lala M, Bazzi L, WahlDR SMJ, et al. Comparison of stereotactic body radiation therapy and radiofrequency ablation in the treatment of intrahepatic metastases. Int J Radiat Oncol Biol Phys. 2018;100(4):950–8.PubMed
29.
Petrelli F, Comito T, Barni S, Pancera G, Scorsetti M, Ghidini A. Stereotactic body radiotherapy for colorectal cancer liver metastases: a systematic review. Radiother Oncol. 2018;129(3):427–34.PubMed
30.
Joo JH, Park JH, Kim JC, Yu CS, Lim SB, Park IJ, et al. Local control outcomes using stereotactic body radiation therapy for liver metastases from colorectal cancer. Int J Radiat Oncol Biol Phys. 2017;99(4):876–83.PubMed
31.
Méndez Romero A, Keskin-Cambay F, van Os RM, Nuyttens JJ, Heijmen BJM, Ijzermans JNM, et al. Institutional experience in the treatment of colorectal liver metastases with stereotactic body radiation therapy. Rep Pract Oncol Radiother. 2017;22(2):126–31.PubMed
32.
Vera R, González-Flores E, Rubio C, Urbano J, Valero Camps M, Ciampi-Dopazo JJ. Multidisciplinary management of liver metastases in patients with colorectal cancer: a consensus of SEOM, AEC, SEOR, SERVEI, and SEMNIM. Clin Transl Oncol. 2020;22:647–62.PubMed
Metadata
Title
Stereotactic body radiation therapy for liver metastasis from colorectal cancer: size matters
Authors
S. Flamarique
M. Campo
G. Asín
S. Pellejero
A. Viúdez
F. Arias
Publication date
01-12-2020
Publisher
Springer International Publishing
Published in
Clinical and Translational Oncology / Issue 12/2020
Print ISSN: 1699-048X
Electronic ISSN: 1699-3055
DOI
https://doi.org/10.1007/s12094-020-02375-x

Other articles of this Issue 12/2020

Clinical and Translational Oncology 12/2020 Go to the issue

Review Article

Tumor microenvironment, immune response and post-radiotherapy tumor clearance

Review Article

Potential biomarkers for early detection of pancreatic ductal adenocarcinoma

Review Article

Research progress of tumor microenvironment and tumor-associated macrophages

Research Article

Potential roles of lymphovascular space invasion based on tumor characteristics provide important prognostic information in T1 tumors with ER and HER2 positive breast cancer

Review Article

Maintenance treatment in advanced HER2-negative gastric cancer

Research Article

hsa_circ_0121582 inhibits leukemia growth by dampening Wnt/β-catenin signaling
Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Watch now

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras
Prof. Fabrice Barlesi
Developed by: Springer Medicine
Image Credits